Lupin to Invest $250 Million in New US Manufacturing Facility; Stock Rises 3.89%

Mumbai | Thursday, October 9, 2025 – The shares of Lupin Limited (NSE: LUPIN, BSE: 500257) soared by 3.89% (reaching ₹ 1,979.80 at 10:30 AM) after the pharma company announced plans to establish a state-of-the-art manufacturing plant in Coral Springs, Florida. The total investment of the project will be ₹2090 ($250 million) for a period of five years. The new US-based facility will help the enterprise in strengthening its respiratory portfolio.

New US Facility to Strengthen Respiratory Portfolio

The 70000 sq ft proposed facility will spread across five acres. The facility will have the capability to produce over 25 critical respiratory medicines, including the lifesaving albuterol inhalers used for asthma and respiratory disorders. The site will cater for both domestic (US) and supply chain diversification, thereby reinforcing Lupin’s position as a global leader in respiratory therapies.

The project is expected to generate more than 200 long-term skilled jobs in Broward County by 2030 and will serve as a key anchor for U.S. production of critical respiratory treatments.

Management’s Take

As per the Florida Secretary of Commerce, Alex Kelly, the move by Lupin will help Florida’s advanced manufacturing capabilities and further enhance the medicine security of the country. The CTO of Lupin, Christoph Funke also underlined that setting up the new facility has been part of the company’s growth facility with a commitment towards innovation, quality and supply chain reliability.

Key Project Highlights

The project entails a $250 million investment over five years to establish a 70,000 sq. ft. facility on over 5 acres in Coral Springs, Florida. Focused on producing over 25 respiratory medicines, the initiative is expected to create 200 jobs by 2030. Backed by tax credits and state-level incentives, the development underscores a strong public-private collaboration to boost regional healthcare manufacturing. With construction and expansion planned through 2030, the project signifies a long-term commitment to innovation, local employment, and advanced pharmaceutical production.

Stock Performance Snapshot (10:30 AM)

The stock is currently trading at ₹1,979.80, marking a 3.89% rise from its previous close of ₹1,905.60. During the day, it moved within the ₹1,930.60–₹1,984.20 range, showing moderate volatility. Over the past year, the stock has traded between ₹1,795.20 and ₹2,402.90, reflecting resilience despite market fluctuations. With a market capitalisation of ₹90,296.46 crore and a P/E ratio of 23.62, the company demonstrates strong valuation metrics. Its inclusion in the Nifty Midcap 50 index highlights its significance among mid-sized growth-oriented firms.

Lupin is one of the major pharmaceutical companies of India and is headquartered in Mumbai. It has a major global presence in over 100 markets. The company has 15 production facilities with 7 R&D centres in different parts of the world and employs more than 24000 people. Lupin’s U.S. operations are headquartered in Naples, Florida, with a strong focus on respiratory care, cardiovascular, and complex generics.

REF: https://nsearchives.nseindia.com/corporate/Lupin2_08102025182704_SE_LetterwithPressRelease_08102025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations